Dealing with the Deconstructors

While Big Pharma will continue to orchestrate the processes that move new compounds along the value chain from discovery to market, the value chain itself increasingly transcends company boundaries. A variety of new focused businesses, based on services and technologies, have emerged, differing greatly from the integrated model embraced by today's major players. Big Pharma's critical decisions about when to partner and when to compete with these new entrants will be based not only on the capabilities and market position of the new players but also on the strategies, culture and organization of traditional drug firms.